Almac Discovery, which is focused on discovering innovative therapeutics for the treatment of cancer, published its findings on the discovery and characterisation of highly potent, selective inhibitors of ubiquitin-specific protease 7 (USP7), online in the journal Nature Chemical Biology in December. The Almac compounds stabilise an important biological protein, which in, turn can inhibit tumour development.
Research Highlighted in Nature Chemical Biology
January 29, 2018
Now, Nature Chemical Biology has spotlighted Almac Discovery’s work in its February issue, highlighting the promise of the Almac compounds as being “potent and specific small-molecule inhibitors of a long-sought-after anticancer drug target” and described the work as “a tour-de-force report of perhaps the most potent small-molecule inhibitor of USP7 to date”. The Almac team anticipates that these chemical probes will be of direct utility to the research community.
Stephen Barr, President & Managing Director, commented:
“We are delighted to see our novel research highlighted in Nature Chemical Biology. This is further evidence of the expertise and understanding the team possess in relation to DUB drug discovery.”